Given that A2AR-edited CAR T cells will remain subject to these other immunosuppressive pathways, we believe that in future studies, it will be of interest to investigate targeting multiple suppressive genes using CRISPR/Cas9 to further protect CAR T cells against tumor-induced immunosuppression. Here, ADORA2A is linked to neoplasm.